Medicus Pharma
MDCX
7 hedge funds and large institutions have $11.4M invested in Medicus Pharma in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
203% more capital invested
Capital invested by funds: $3.74M → $11.4M (+$7.61M)
133% more funds holding
Funds holding: 3 → 7 (+4)
10.04% more ownership
Funds ownership: 12.72% → 22.76% (+10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.97M |
| 2 |
ICP
Interchange Capital Partners
Pittsburgh,
Pennsylvania
|
+$643K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$178K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$66.8K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$15.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$42K |
MDCX Hedge Fund Activity: Q1 2025 in Review
7 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Medicus Pharma (MDCX) for Q1 2025, worth a combined $11.4M — up 203% from $3.74M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MDCX positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.97M. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $42K sold.
- 7 institutional investors held Medicus Pharma (MDCX) as of Q1 2025, up from 3 in Q4 2024.
- Funds reported $11.4M of Medicus Pharma stock for Q1 2025, up 203% quarter-over-quarter.
- 5 funds opened new Medicus Pharma positions in Q1 2025 and 1 closed out, a net change of +4 holders.
- The largest Medicus Pharma buyer in Q1 2025 was Armistice Capital, an estimated $3.97M added.
- The largest Medicus Pharma seller in Q1 2025 was Royal Bank of Canada, an estimated $42K sold.
Based on aggregated 13F filings for Q1 2025.